



## **Introducing government use of patents on essential medicines in Thailand, 2006 - 2007**

**Policy analysis with key lessons learned and recommendations**



Sripen Tantivess  
Nusaraporn Kessomboon  
Chotiros Laongbua

International Health Policy Program, Thailand  
June 2008

# Table of contents

Preface.....	iii
Acknowledgements.....	iv
Abstract.....	v
Table of contents.....	vii
List of tables and figures.....	x
List of abbreviations.....	xiii
1. Introduction.....	1
2. Background information: International framework on medicine patents and the Thai experience.....	6
2.1 TRIPS agreement and public health.....	6
2.2 TRIPS flexibilities and the Doha Declaration on TRIPS and Public Health.....	8
2.3 Experiences of developing countries on the use of compulsory licensing for medicines.....	11
2.4 Past effort to ensure access to medicines in Thailand.....	16
2.5 Price negotiations prior to the government use of medicine patents in 2006-7.....	23
3. Agenda setting and adoption of the Thai policy on government use of medicine patents.....	26
3.1 How the use of TRIPS flexibilities attracted policymakers.....	26
3.2 On what grounds the government use policy was adopted?.....	32
3.3 The motives behind the introduction of government use provision.....	35
4. How the government use of medicine patents was put into operation.....	41
4.1 The MOPH's 'White Paper'.....	12
4.2 The establishment of new government mechanisms.....	44

4.3	Networking with local and international partners.....	49
4.4	Importation and distribution of medicines under the government use programme .....	52
4.5	Seeking support on the use of TRIPS flexibilities from the WHO.....	54
5.	Interplay between local stakeholders.....	58
6.	The roles of international organisations.....	71
7.	Pressing movements of drug companies, their representatives and country governments.....	78
7.1	Motives of the opposition to the government use policy.....	78
7.2	Reactions of some industrialized nations.....	81
7.3	Pressing movements of the trans-national drug industry.....	95
8.	Non-governmental organisations as key players.....	113
9.	Immediate benefits of the enforcement of government use measure.....	119
9.1	Beneficial implications for Thailand's health systems.....	119
9.2	Spill-over effects of the Thai action.....	125
10.	The way forward.....	128
10.1	Anticancer: medicines in the government use pipeline.....	129
10.2	Government's plan on local drug production.....	131
10.3	Looking beyond the 2007 general election: will the government use policy continue?.....	131
11.	Discussion, lessons learned and policy recommendations.....	134
11.1	Agenda setting and policy adoption.....	134
11.2	Policy formulation and implementation.....	136

11.3	Policy networks: exchanges of resources and their contributions.....	139
11.4	Looking at the Thai CL policy through the lens of power.....	142
11.5	Why Thailand's government use initiative generated serious tensions: the matters of interests and awareness of potential policy transfer.....	144
11.6	Lessons drawn on the government use of medicine patents in Thailand.....	147
11.7	Policy recommendations.....	149
	References.....	151